PET with F-18- fluorothymidine on patients with head and neck cancer prior to and during radiation therapy allows physicians assess early outcomes.
PET imaging with F-18- fluorothymidine on patients with head and neck cancer prior to and during radiation therapy allows physicians to assess early loco-regional clinical outcomes, according to a study published in the October issue of The Journal of Nuclear Medicine.
Studies have shown F-18-fluorodeoxyglucose (FDG) PET may be used to assess treatment response, but may produce false positives. Researchers from Kagawa University in Japan studied 28 patients with head and neck squamous carcinomas (HNSCCs) between May 2006 and September 2010, who underwent both FDG and F-18- fluorothymidine (FLT) PET imaging before treatment, at four weeks after the start of treatment and again five weeks after therapy was finished. Both primary and metastatic lesions were assessed. The researchers were looking for regions of focally increased metabolism, which were analyzed in relation to residual accumulation and local disease control.
Researchers found that during radiation therapy, F-18-FLT uptake accumulation disappeared in 34 of 54 lesions (63 percent) and the negative predictive value was 97 percent. The negative predictive value for the F-18-FDG uptake was 100 percent, and only nine lesions (16 percent) in all showed complete absence of accumulation.
“The specificity and overall accuracy of F-FLT PET were significantly higher than those of F-FDG PET both during and after RT,” wrote the authors. The high significance, the authors said, was due to the results of the evaluations of the primary lesions.
“With the development of new molecular imaging agents, it’s now up to clinical researchers to utilize them to assess the characteristics of malignant tumors and their therapeutic response to chemotherapy, radiotherapy, and molecular targeting therapy,” Hiroshi Hoshikawa, MD, the study’s lead author, said in a press release. “We hope that our findings will be helpful in understanding the significance of F-18-FLT-PET.”
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.